Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care

Chloe Goldman, Jeremy Tchack, Eric M. Robinson, Sung Won Han, Una Moran, David Polsky, Russell S. Berman, Richard L. Shapiro, Patrick A. Ott, Iman Osman, Hua Zhong, Anna C. Pavlick, Melissa Ann Wilson

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: Since 2011, metastatic melanoma treatment has evolved with commercial approval of BRAF- and MEK-targeted therapy and CTLA-4- and PD-1-blocking antibodies (immune checkpoint inhibitors, ICI). While novel therapies have demonstrated improved prognosis in clinical trials, few studies have examined the evolution of prognosis and toxicity of these drugs among an unselected population. We assess whether survival and toxicity reported in trials, which typically exclude most patients with brain metastases and poor performance status, are recapitulated within a commercial access population. Methods: 182 patients diagnosed with stage IV melanoma from July 2006 to December 2013 and treated with BRAF- and/or MEK-targeted therapy or ICI were prospectively studied. Outcomes and clinicopathologic differences between trial and commercial cohorts were assessed. Results: Patients receiving commercial therapy (vs. on trial) had poorer prognostic features (i.e., brain metastases) and lower median overall survival (mOS) when assessed across all treatments (9.2 vs. 17.5 months, p = 0.0027). While toxicity within trial and commercial cohorts did not differ, patients who experienced toxicity had increased mOS (p < 0.001), irrespective of stratification by trial status or therapy. Conclusion: Metastatic melanoma patients receiving commercial treatment may represent a different clinical population with poor prognostic features compared to trial patients. Toxicity may prognosticate treatment benefit.

Original languageEnglish
Pages (from-to)164-176
Number of pages13
JournalOncology (Switzerland)
Volume93
Issue number3
DOIs
Publication statusPublished - 2017 Aug 1
Externally publishedYes

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Standard of Care
Melanoma
Clinical Trials
Therapeutics
Survival
Population
Neoplasm Metastasis
Blocking Antibodies
Brain
Drug-Related Side Effects and Adverse Reactions

Keywords

  • Adverse events
  • Immune-related adverse events
  • Immunotherapy
  • Metastatic melanoma
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care. / Goldman, Chloe; Tchack, Jeremy; Robinson, Eric M.; Han, Sung Won; Moran, Una; Polsky, David; Berman, Russell S.; Shapiro, Richard L.; Ott, Patrick A.; Osman, Iman; Zhong, Hua; Pavlick, Anna C.; Wilson, Melissa Ann.

In: Oncology (Switzerland), Vol. 93, No. 3, 01.08.2017, p. 164-176.

Research output: Contribution to journalArticle

Goldman, C, Tchack, J, Robinson, EM, Han, SW, Moran, U, Polsky, D, Berman, RS, Shapiro, RL, Ott, PA, Osman, I, Zhong, H, Pavlick, AC & Wilson, MA 2017, 'Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care', Oncology (Switzerland), vol. 93, no. 3, pp. 164-176. https://doi.org/10.1159/000475715
Goldman, Chloe ; Tchack, Jeremy ; Robinson, Eric M. ; Han, Sung Won ; Moran, Una ; Polsky, David ; Berman, Russell S. ; Shapiro, Richard L. ; Ott, Patrick A. ; Osman, Iman ; Zhong, Hua ; Pavlick, Anna C. ; Wilson, Melissa Ann. / Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care. In: Oncology (Switzerland). 2017 ; Vol. 93, No. 3. pp. 164-176.
@article{3280c93e16fd4a9e942eec7c3c4a8e12,
title = "Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care",
abstract = "Objectives: Since 2011, metastatic melanoma treatment has evolved with commercial approval of BRAF- and MEK-targeted therapy and CTLA-4- and PD-1-blocking antibodies (immune checkpoint inhibitors, ICI). While novel therapies have demonstrated improved prognosis in clinical trials, few studies have examined the evolution of prognosis and toxicity of these drugs among an unselected population. We assess whether survival and toxicity reported in trials, which typically exclude most patients with brain metastases and poor performance status, are recapitulated within a commercial access population. Methods: 182 patients diagnosed with stage IV melanoma from July 2006 to December 2013 and treated with BRAF- and/or MEK-targeted therapy or ICI were prospectively studied. Outcomes and clinicopathologic differences between trial and commercial cohorts were assessed. Results: Patients receiving commercial therapy (vs. on trial) had poorer prognostic features (i.e., brain metastases) and lower median overall survival (mOS) when assessed across all treatments (9.2 vs. 17.5 months, p = 0.0027). While toxicity within trial and commercial cohorts did not differ, patients who experienced toxicity had increased mOS (p < 0.001), irrespective of stratification by trial status or therapy. Conclusion: Metastatic melanoma patients receiving commercial treatment may represent a different clinical population with poor prognostic features compared to trial patients. Toxicity may prognosticate treatment benefit.",
keywords = "Adverse events, Immune-related adverse events, Immunotherapy, Metastatic melanoma, Targeted therapy",
author = "Chloe Goldman and Jeremy Tchack and Robinson, {Eric M.} and Han, {Sung Won} and Una Moran and David Polsky and Berman, {Russell S.} and Shapiro, {Richard L.} and Ott, {Patrick A.} and Iman Osman and Hua Zhong and Pavlick, {Anna C.} and Wilson, {Melissa Ann}",
year = "2017",
month = "8",
day = "1",
doi = "10.1159/000475715",
language = "English",
volume = "93",
pages = "164--176",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "3",

}

TY - JOUR

T1 - Outcomes in Melanoma Patients Treated with BRAF/MEK-Directed Therapy or Immune Checkpoint Inhibition Stratified by Clinical Trial versus Standard of Care

AU - Goldman, Chloe

AU - Tchack, Jeremy

AU - Robinson, Eric M.

AU - Han, Sung Won

AU - Moran, Una

AU - Polsky, David

AU - Berman, Russell S.

AU - Shapiro, Richard L.

AU - Ott, Patrick A.

AU - Osman, Iman

AU - Zhong, Hua

AU - Pavlick, Anna C.

AU - Wilson, Melissa Ann

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Objectives: Since 2011, metastatic melanoma treatment has evolved with commercial approval of BRAF- and MEK-targeted therapy and CTLA-4- and PD-1-blocking antibodies (immune checkpoint inhibitors, ICI). While novel therapies have demonstrated improved prognosis in clinical trials, few studies have examined the evolution of prognosis and toxicity of these drugs among an unselected population. We assess whether survival and toxicity reported in trials, which typically exclude most patients with brain metastases and poor performance status, are recapitulated within a commercial access population. Methods: 182 patients diagnosed with stage IV melanoma from July 2006 to December 2013 and treated with BRAF- and/or MEK-targeted therapy or ICI were prospectively studied. Outcomes and clinicopathologic differences between trial and commercial cohorts were assessed. Results: Patients receiving commercial therapy (vs. on trial) had poorer prognostic features (i.e., brain metastases) and lower median overall survival (mOS) when assessed across all treatments (9.2 vs. 17.5 months, p = 0.0027). While toxicity within trial and commercial cohorts did not differ, patients who experienced toxicity had increased mOS (p < 0.001), irrespective of stratification by trial status or therapy. Conclusion: Metastatic melanoma patients receiving commercial treatment may represent a different clinical population with poor prognostic features compared to trial patients. Toxicity may prognosticate treatment benefit.

AB - Objectives: Since 2011, metastatic melanoma treatment has evolved with commercial approval of BRAF- and MEK-targeted therapy and CTLA-4- and PD-1-blocking antibodies (immune checkpoint inhibitors, ICI). While novel therapies have demonstrated improved prognosis in clinical trials, few studies have examined the evolution of prognosis and toxicity of these drugs among an unselected population. We assess whether survival and toxicity reported in trials, which typically exclude most patients with brain metastases and poor performance status, are recapitulated within a commercial access population. Methods: 182 patients diagnosed with stage IV melanoma from July 2006 to December 2013 and treated with BRAF- and/or MEK-targeted therapy or ICI were prospectively studied. Outcomes and clinicopathologic differences between trial and commercial cohorts were assessed. Results: Patients receiving commercial therapy (vs. on trial) had poorer prognostic features (i.e., brain metastases) and lower median overall survival (mOS) when assessed across all treatments (9.2 vs. 17.5 months, p = 0.0027). While toxicity within trial and commercial cohorts did not differ, patients who experienced toxicity had increased mOS (p < 0.001), irrespective of stratification by trial status or therapy. Conclusion: Metastatic melanoma patients receiving commercial treatment may represent a different clinical population with poor prognostic features compared to trial patients. Toxicity may prognosticate treatment benefit.

KW - Adverse events

KW - Immune-related adverse events

KW - Immunotherapy

KW - Metastatic melanoma

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85028633790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028633790&partnerID=8YFLogxK

U2 - 10.1159/000475715

DO - 10.1159/000475715

M3 - Article

C2 - 28601879

AN - SCOPUS:85028633790

VL - 93

SP - 164

EP - 176

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3

ER -